Endocrinol Metab.  2010 Jun;25(2):159-160. 10.3803/EnM.2010.25.2.159.

Response: Comparison of the Efficacy of Octreotide Long-acting Repeatable and Lanreotide Autogel in Acromegalic Patients (J Korean Endocr Soc 25:37-45, 2010)

• Kim SY
• Kim D

• KMID: 2169025
• DOI: http://doi.org/10.3803/EnM.2010.25.2.159

Abstract

No abstract available.

MeSH Terms

Humans
Octreotide
Peptides, Cyclic
Somatostatin
Octreotide
Peptides, Cyclic
Somatostatin

Reference

References

1. Colao A, Pivonello R, Auriemma RS, Briganti F, Galdiero M, Tortora F, Caranci F, Cirillo S, Lombardi G. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab. 91:2112–2118. 2006.

2. Kim JY, Jee JH, Yoon CH, Chung YJ, Lee BW, Cho GY, Kim SY, Chung JH, Min YK, Lee MS, Lee MK, Kim KW. Efficacy of octreotide LAR in acromegalic patients. J Korean Soc Endocrinol. 20:344–352. 2005.

3. Yang SJ, Seo YJ, Eun CR, Chung HS, Choi HJ, Kim NH, Kim HS, Park JR, Kim DJ, Yoo HJ, Park SY, Lee YJ, Ryu OH, Kim HY, Lee KW, Seo JA, Kim SG, Choi DS, Baik SH. Therapeutic effects of a long-acting formulation of lanreotide in Korean patients with acromegaly. Korean J Med. 73:50–57. 2007.

4. Jallad RS, Musolino NR, Salgado LR, Bronstein MD. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution. Clin Endocrinol (Oxf). 63:168–175. 2005.

5. Mercado M, Borges F, Bouterfa H, Chang TC, Chervin A, Farrall AJ, Patocs A, Petersenn S, Podoba J, Safari M, Wardlaw J. SMS995B2401 Study Group. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf). 66:859–868. 2007.

6. Andries M, Glintborg D, Kvistborg A, Hagen C, Andersen M. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-I in patients with acromegaly Clin Endocrinol (Oxf). 68:473–480. 2008.

7. Murray RD, Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab. 93:2957–2968. 2008.